CL2014002497A1 - Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local. - Google Patents

Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.

Info

Publication number
CL2014002497A1
CL2014002497A1 CL2014002497A CL2014002497A CL2014002497A1 CL 2014002497 A1 CL2014002497 A1 CL 2014002497A1 CL 2014002497 A CL2014002497 A CL 2014002497A CL 2014002497 A CL2014002497 A CL 2014002497A CL 2014002497 A1 CL2014002497 A1 CL 2014002497A1
Authority
CL
Chile
Prior art keywords
dihydrooxazol
triazolo
yloxy
pyridin
methylphenyl
Prior art date
Application number
CL2014002497A
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CL2014002497A1 publication Critical patent/CL2014002497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CL2014002497A 2012-03-23 2014-09-22 Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local. CL2014002497A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23

Publications (1)

Publication Number Publication Date
CL2014002497A1 true CL2014002497A1 (es) 2014-11-14

Family

ID=48048296

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002497A CL2014002497A1 (es) 2012-03-23 2014-09-22 Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.

Country Status (30)

Country Link
US (3) US20150110780A1 (es)
EP (4) EP4252855A3 (es)
JP (6) JP2015514075A (es)
KR (3) KR102317166B1 (es)
CN (2) CN104203279B (es)
AU (4) AU2013234921A1 (es)
CA (1) CA2867723C (es)
CL (1) CL2014002497A1 (es)
CO (1) CO7071139A2 (es)
CY (2) CY1120204T1 (es)
DK (2) DK2827900T3 (es)
ES (2) ES2673165T3 (es)
HK (1) HK1206276A1 (es)
HR (1) HRP20180659T1 (es)
HU (2) HUE037966T2 (es)
IL (3) IL234627B (es)
LT (1) LT2827900T (es)
MX (1) MX354024B (es)
MY (2) MY202114A (es)
NZ (4) NZ756264A (es)
PH (1) PH12014502032A1 (es)
PL (2) PL3400943T3 (es)
PT (2) PT3400943T (es)
RS (1) RS57140B1 (es)
RU (2) RU2018138976A (es)
SG (1) SG11201405954YA (es)
SI (2) SI2827900T1 (es)
TR (1) TR201808450T4 (es)
UA (1) UA122044C2 (es)
WO (1) WO2013142875A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2765990B1 (en) 2011-10-14 2017-09-06 Array Biopharma, Inc. Solid dispersion
SG11201401460PA (en) 2011-10-14 2014-09-26 Array Biopharma Inc POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EP3773726A1 (en) * 2018-04-09 2021-02-17 Moshe Giladi Treating tumors with ttfields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
JP2022544234A (ja) 2019-08-12 2022-10-17 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
EP4084778B1 (en) * 2019-12-30 2023-11-01 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
DK1660090T3 (da) 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
AU2005251722B2 (en) 2004-06-03 2009-11-12 Smithkline Beecham (Cork) Limited Cancer treatment method
EP1971601B1 (en) * 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
AU2007235199B8 (en) 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
HUE025507T2 (en) * 2008-03-18 2016-02-29 Genentech Inc Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use
EP2765990B1 (en) 2011-10-14 2017-09-06 Array Biopharma, Inc. Solid dispersion
SG11201401460PA (en) 2011-10-14 2014-09-26 Array Biopharma Inc POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer

Also Published As

Publication number Publication date
CA2867723A1 (en) 2013-09-26
MY202114A (en) 2024-04-04
HUE053156T2 (hu) 2021-06-28
US11504370B2 (en) 2022-11-22
MY174883A (en) 2020-05-20
CY1123837T1 (el) 2022-05-27
DK3400943T3 (da) 2021-02-08
NZ741615A (en) 2019-10-25
KR102317166B1 (ko) 2021-10-26
CA2867723C (en) 2022-11-08
JP7404485B2 (ja) 2023-12-25
KR20200115656A (ko) 2020-10-07
JP2017141302A (ja) 2017-08-17
MX354024B (es) 2018-02-08
JP2022190126A (ja) 2022-12-22
EP4252855A2 (en) 2023-10-04
US20190255051A1 (en) 2019-08-22
SG11201405954YA (en) 2014-10-30
JP2019081792A (ja) 2019-05-30
KR102490961B1 (ko) 2023-01-19
PL2827900T3 (pl) 2018-08-31
HRP20180659T1 (hr) 2018-06-01
SI2827900T1 (en) 2018-06-29
US20150110780A1 (en) 2015-04-23
JP2024019526A (ja) 2024-02-09
CY1120204T1 (el) 2018-12-12
IL269205B (en) 2020-06-30
US20230190749A1 (en) 2023-06-22
PH12014502032A1 (en) 2014-11-24
DK2827900T3 (en) 2018-05-07
KR20210131426A (ko) 2021-11-02
AU2019203618A1 (en) 2019-06-13
IL269205A (en) 2019-11-28
UA122044C2 (uk) 2020-09-10
JP6898960B2 (ja) 2021-07-07
NZ724544A (en) 2018-05-25
RU2672575C2 (ru) 2018-11-16
CN104203279B (zh) 2018-10-30
RU2014142700A (ru) 2016-05-20
AU2021261849A1 (en) 2021-12-02
AU2013234921A1 (en) 2014-10-02
AU2019203618B2 (en) 2021-08-05
RU2018138976A3 (es) 2022-04-08
CN109223791A (zh) 2019-01-18
AU2017272232B2 (en) 2019-02-28
LT2827900T (lt) 2018-05-10
ES2673165T3 (es) 2018-06-20
EP3400943B1 (en) 2020-12-02
WO2013142875A1 (en) 2013-09-26
IL234627B (en) 2018-10-31
IL261659A (en) 2018-10-31
PT3400943T (pt) 2021-02-02
TR201808450T4 (tr) 2018-07-23
HUE037966T2 (hu) 2018-09-28
AU2017272232C1 (en) 2019-08-15
EP3842044A1 (en) 2021-06-30
RU2018138976A (ru) 2018-12-06
NZ630843A (en) 2017-01-27
SI3400943T1 (sl) 2021-03-31
MX2014011437A (es) 2014-11-10
EP2827900B1 (en) 2018-03-21
RS57140B1 (sr) 2018-07-31
JP2015514075A (ja) 2015-05-18
PT2827900T (pt) 2018-06-14
HK1206276A1 (en) 2016-01-08
ES2855142T3 (es) 2021-09-23
AU2017272232A1 (en) 2018-01-04
EP4252855A3 (en) 2023-11-15
CN104203279A (zh) 2014-12-10
EP3400943A1 (en) 2018-11-14
KR102160462B1 (ko) 2020-09-28
EP2827900A1 (en) 2015-01-28
CO7071139A2 (es) 2014-09-30
JP2021178820A (ja) 2021-11-18
KR20140139009A (ko) 2014-12-04
NZ756264A (en) 2022-09-30
PL3400943T3 (pl) 2021-06-14

Similar Documents

Publication Publication Date Title
CL2014002497A1 (es) Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.
CY1119837T1 (el) Στερεα διασπορα
BR112013033940A2 (pt) terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
BRPI1015006A2 (pt) uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
BR112015006019A2 (pt) composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
CL2013003306A1 (es) Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BRPI0917119A2 (pt) composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BR112015001830A2 (pt) composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
UY34264A (es) Compuestos de fórmula genérica 4-(8-metoxi-1-(1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H- imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y sus sales.
BR112015004547A8 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BR112013013898A2 (pt) compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.